Question: What are the implications of discordancies between estimated glomerular filtration rates (eGFR) derived from serum creatinine (eGFRcr) versus those from cystatin C (eGFRcys) for individuals with cancer?
Outcome: Within a study group of 1869 adult cancer patients, those exhibiting an eGFRcys exceeding their eGFRcr by over 30% faced elevated risks of surpassing therapeutic vancomycin levels, experiencing hyperkalemia linked to trimethoprim-sulfamethoxazole, encountering toxic effects of baclofen, exhibiting elevated digoxin levels, and encountering heightened mortality risk within a 30-day span.
Significance: The study's outcomes underscore that patients whose eGFRcys is more than 30% lower than their eGFRcr encounter a higher frequency of medication-related adverse events. This highlights the need for further investigations aimed at enhancing and customizing glomerular filtration rate calculations and medication dosage adjustments in the context of cancer patients.
Link To Original Article https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2806843